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We sought to define whether there are intrinsic molecular sub-
types of high-grade bladder cancer. Consensus clustering per-
formed on gene expression data from a meta-dataset of high-
grade, muscle-invasive bladder tumors identified two intrinsic,
molecular subsets of high-grade bladder cancer, termed “luminal”
and “basal-like,” which have characteristics of different stages of
urothelial differentiation, reflect the luminal and basal-like molec-
ular subtypes of breast cancer, and have clinically meaningful dif-
ferences in outcome. A gene set predictor, bladder cancer analysis
of subtypes by gene expression (BASE47) was defined by predic-
tion analysis of microarrays (PAM) and accurately classifies the
subtypes. Our data demonstrate that there are at least two mo-
lecularly and clinically distinct subtypes of high-grade bladder can-
cer and validate the BASE47 as a subtype predictor. Future studies
exploring the predictive value of the BASE47 subtypes for stan-
dard of care bladder cancer therapies, as well as novel subtype-
specific therapies, will be of interest.
In the United States, urothelial carcinoma (UC) of the bladderis the fourth most common malignancy in men and the ninth
most common in women, with 72,570 new cases and 15,210 deaths
expected in 2013 (1). Bladder cancer is heterogeneous and can
be histologically divided into low-grade and high-grade disease.
Whereas low-grade tumors are almost invariably noninvasive (Ta),
high-grade tumors can be classified based on invasion into the
muscularis propria of the bladder, as non–muscle invasive bladder
cancer (NMIBC; Tis, Ta, T1) or muscle invasive bladder cancer
(MIBC; ≥T2). Low-grade tumors are associated with a high rate of
recurrence but an excellent overall prognosis, with a 5-y survival in
the range of 90%. In contrast, high-grade MIBC has a relatively
poor 5-y overall survival, 68% for T2 and decreasing to 15% for
non–organ-confined disease (i.e., pT3 and pT4) (1, 2).
Along with divergent pathologies and prognosis, low-grade
and high-grade UCs are associated with distinct genetic alterations.
For example, low-grade UCs are enriched for activating mutations
in fibroblast growth factor 3 (FGFR3), phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), and in-
activating lysine (K)-specific demethylase 6A (KDM6A) muta-
tions, whereas high-grade, muscle-invasive tumors are enriched for
tumor protein p53 (TP53) and retinoblastoma 1 (RB1) pathway
alterations (3–10).
Several reports have examined the gene expression profiles of
primary bladder tumors. From these studies, it is apparent that
low-grade noninvasive and high-grade muscle-invasive tumors
harbor distinct gene expression patterns, and that further mo-
lecular subsets can be identified within low-grade and high-grade
tumors (5, 11–14). Moreover, a number of gene signatures have
been developed that can predict tumor stage, lymph node me-
tastases, and bladder cancer progression (11–13, 15–18). There
are established gene expression patterns that differentiate low-
grade and high-grade tumors; however, there are little data
identifying intrinsic subtypes specifically within high-grade dis-
ease. We have identified two intrinsic molecular subsets of high-
grade bladder cancer, termed “luminal” and “basal-like,” with
differences in clinical outcome. In addition, we have developed
a 47-gene predictor, bladder cancer analysis of subtypes by ex-
pression (BASE47), which can accurately classify high-grade
UCs into luminal and basal-like tumors. The molecular subtypes
appear to reflect different stages of urothelial differentiation and
strikingly recapitulate aspects of breast cancer biology, including
a claudin-low subtype.
Results
Consensus Clustering Reveals Two Distinct Molecular Subtypes of
High-Grade Bladder Cancer. Previous studies examining the gene
expression changes associated with bladder cancer have assessed
both low-grade and high-grade tumors in aggregate (5, 11–13, 19,
20). In the present study, we looked exclusively for intrinsic
subtypes of high-grade disease agnostic to clinical stage or out-
come. We first created a meta-dataset of 262 high-grade muscle-
invasive tumors, curated from four publically available datasets
(12, 19–21) (SI Appendix, Table S1). In parallel, an independent
set of 49 high-grade tumors from Memorial Sloan-Kettering
Cancer Center (MSKCC) served as a validation set (8). In both the
meta-dataset and the MSKCC dataset, consensus clustering iden-
tified two groups (designated K1 and K2) as the optimal number of
molecular subtypes, as defined by the criterion of subclass stability
(Fig. 1 A and B and SI Appendix, Fig. S1 A and B).
To validate that the gene expression changes that define the
two subtypes are similar, we determined the correlation between
the median gene expression (using all common genes between
datasets) for each subtype (Fig. 1C; yellow, correlation; blue,
anticorrelation). There appeared to be a high level of correlation
between the meta-dataset K1 cluster andMSKCCK2 cluster, as well
as between the meta-dataset K2 cluster and MSKCC K1 cluster.
Significance
The identification of molecular subtype heterogeneity in breast
cancer has allowed a deeper understanding of breast cancer
biology. We present evidence that there are two intrinsic
subtypes of high-grade bladder cancer, basal-like and luminal,
which reflect the hallmarks of breast biology. Moreover, we
have developed an accurate gene set predictor of molecular
subtype, the BASE47, that should allow the incorporation of
subtype stratification into clinical trials. Further clinical, etio-
logic, and therapeutic response associations will be of interest
in future investigations.
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Thus, the intrinsic molecular subtypes defined by independent dis-
covery in the two datasets are defined by highly concordant gene
expression patterns and suggest that the subtypes are robust.
Intrinsic Molecular Subtypes of Bladder Cancer Differentially Express
Markers of Urothelial Differentiation. To understand the gene ex-
pression patterns that differentiate the intrinsic subtypes of high-
grade bladder cancer, we performed two-class significance
analysis of microarrays (SAM) comparing clusters K1 and K2
from the meta-dataset. A total of 2,393 genes were found to be
differentially expressed [false discovery rate (FDR) cutoff, 0] (SI
Appendix, Table S2). The intrinsic molecular subtypes were
characterized by gene expression patterns representative of
urothelial differentiation. Cluster K1 of the meta-dataset
expressed high levels of the high molecular weight keratins
(HMWKs) keratin 14 (KRT14), keratin 5 (KRT5), and keratin 6B
(KRT6B), as well as of CD44 molecule (CD44), which are
expressed in urothelial basal cells (22, 23). In contrast, cluster K2
expressed high levels of uroplakins [uroplakin 1B (UPK1B),
uroplakin 2 (UPK2), and uroplakin 3A (UPK3A)], as well as
the low molecular weight keratin (LMWK) keratin 20 (KRT20)
(Fig. 1D), characteristic of urothelial umbrella cells (23). More-
over, the gene expression of KRT5 was inversely correlated with
that of both UPK2 and KRT20 across all tumors (SI Appendix, Fig.
S1 E and F). Similar findings were seen in the MSKCC dataset (SI
Appendix, Fig. S1 C, F, and G).
We performed ingenuity pathway analysis (IPA) to examine
whether processes other than urothelial differentiation were as-
sociated with the intrinsic subtypes. IPA revealed that K1 cluster
tumors were enriched in gene pathways involving cancer, cell
survival, and cell movement (Fig. 1E). In aggregate, these findings
demonstrate that the two molecular subtypes of high-grade MIBC
represent different stages of urothelial differentiation, leading us
to name cluster 1 “basal-like” and cluster 2 “luminal.”
BASE47 Accurately Predicts Basal-Like and Luminal Subtypes. We
next sought to define a minimal set of genes that could accurately
classify bladder tumors into the luminal and basal-like bladder
intrinsic subtypes. To this end, we applied prediction analysis of
microarrays (PAM) to our meta-dataset and derived a 47-gene
signature, BASE47 (SI Appendix, Table S3), that could accu-
rately classify basal-like and luminal tumors relative to consensus
clustering (training error rate, 0.11 and 0.05, respectively) (Fig.
2). A pairwise comparison of the subtype classification by con-
sensus clustering relative to classification by BASE47 showed
a strong correlation in both the meta-dataset and the MSKCC
datasets (both P < 0.001, χ2 test). Cluster analysis using the
MSKCC tumors illustrates the gene expression patterns that
compose the BASE47 (SI Appendix, Fig. S2A).
Intrinsic Bladder Subtypes Have Differential Survival. We next asked
whether the intrinsic bladder subtypes had prognostic signifi-
cance. Basal-like tumors (as identified by BASE47) had signifi-
cantly decreased disease-specific and overall survival (P = 0.0194
and P = 0.0081 respectively) (Fig. 3 A and B). Moreover, of the
clinicopathological features available to us in the MSKCC
dataset, only BASE47 subtype was found to be significant for
disease-specific survival by univariate analysis (SI Appendix, Table
S4 and Fig. S2B).
Furthermore, to assess the prognostic value of the BASE47
relative to published prognostic signatures derived from high-
grade, muscle-invasive tumors, we generated “good” and “poor”
prognosis calls on the MSKCC tumors using the published gene
lists (11, 13) (SI Appendix, Fig. S2 C and D). Neither gene sig-
nature demonstrated prognostic value (SI Appendix, Fig. S3 E
and F). Thus, the BASE47 intrinsic bladder subtypes not only
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Fig. 1. Consensus clustering defines two distinct molecular subtypes of
MIBC. (A) Consensus clustering was performed on 262 muscle-invasive tumors
curated from four publicly available datasets (meta-dataset), yielding two
subtypes. (B) Consensus clustering was performed independently on a dataset
of high-grade bladder tumors obtained fromMSKCC (n = 49). (C) The median
gene expression of all common genes between the datasets were compared,
and the Pearson correlation was plotted (yellow, correlation; blue, anti-
correlation). Numerical values represent the Pearson correlation. (D) Gene
expression of epithelial and urothelial markers were visualized by heatmap,
supervised by ConsensusClusterPlus calls in the meta-dataset. (E) Significantly
differentially expressed genes between K1 and K2 from themeta-dataset and
their respective fold changes, as determined by two-class SAM (2,393 genes;
FDR, 0) were analyzed for predicted pathway enrichment by IPA. Selected
significant pathways enriched in K1 are shown.



































Fig. 2. Generation of the BASE47 subtype predictor. PAM was performed us-
ing the basal-like and luminal subtype calls generated by ConsensusClusterPlus.
A predictor consisting of 47 genes was generated that accurately predicted the
subtypes from the meta-dataset training set (P < 0.001), as well as a MSKCC
validation dataset (45 of 47 genes present; P < 0.001).











Interestingly, whereas the BASE47 predictor was developed on
muscle-invasive tumors, we also noted that when applied to
a meta-dataset of superficial tumors, it classified a significant
proportion them as basal-like (Fig. 3C), suggesting that the intrinsic
subtypes may exist in NMIBC.
Intrinsic Subtypes Are Associated with Distinct Genomic Alterations.
The MSKCC tumor set has been previously characterized for
bladder cancer-relevant genetic alterations (8). We examined the
relative enrichment of these molecular events in the bladder
subtypes (Fig. 3D). Notably, FGFR3 (P < 0.001) and tuberous
sclerosis 1 (TSC1) (P = 0.02) mutations were significantly
enriched in the luminal subtype, whereas RB1 pathway alter-
ations [i.e., RB1 mutations/deletions, Cyclin D1 (CCND1)
amplification, E2F transcription factor 2 (E2F3) amplification, or
Cyclin E1 (CCNE1) amplification] were significantly enriched
in basal-like bladder cancer (P = 0.009).
Multiple studies have shown poorer bladder cancer-specific
outcomes in females compared with males (24). We found a trend
toward enrichment of basal-like tumors in female patients in the
MSKCC dataset (Fig. 3D; P = 0.1137), and a significantly higher
incidence of basal-like bladder cancer in female patients in the
meta-dataset with annotated sex (Fig. 3E). This enrichment of
basal-like bladder cancer may explain in part the poorer bladder
cancer-specific outcomes in women.
Basal-Like Bladder Cancer Is Enriched for the Signatures of Basal-Like
Breast Cancer and Tumor-Initiating Cells. A number of genes fun-
damental for breast development and breast cancer were found
to be coregulated with genes that regulate urothelial development
(SI Appendix, Fig. S3). Moreover, Gene Set Enrichment Analysis
(GSEA) performed on the meta-dataset to identify gene sets
enriched in the intrinsic subtypes found multiple breast cancer-
related gene signatures enriched in the basal-like bladder subtype,
as well as signatures related to mammary stem cells (SI Appendix,
Table S5). In keeping with these findings, we found that a pre-
viously published bladder tumor initiating cell (TIC) signature
(22) was enriched in the basal-like subtype by both hierarchical
clustering (P = 2 × 10−16, χ2 test) (SI Appendix, Fig. S4A) and
GSEA (SI Appendix, Fig. S4B), suggesting that basal-like bladder
cancer has a more “stem-like” phenotype, similar to that described
previously in basal-like breast cancer (25).
Intrinsic Bladder Subtypes Reflect the Attributes of Breast Cancer
Subtypes. We next asked whether the basal-like and luminal
bladder cancer subtypes correlated with any of the previously
defined molecular subtypes of breast cancer (26). To this end, we
generated breast cancer molecular subtype classifications (basal,
Her2-enriched, luminal A, luminal B, and normal-like) on two
independent sets of breast tumors [The Cancer Genome Atlas
(TCGA) (27) and UNC337 (28)] using the PAM50 nearest-
centroid classifier (29). To examine whether the gene expression
patterns of luminal and basal-like bladder cancers were reflected
in the intrinsic breast cancer subtypes, we correlated the centroid
gene expression (using the breast intrinsic gene list) between the
bladder and breast cancer subtypes (Fig. 4A; yellow, correlation;
blue, anticorrelation). Basal-like bladder cancers demonstrated
positive correlations with basal-like breast as well as normal-like
breast cancer subtypes, whereas luminal bladder cancers had
positive correlations with both luminal A and luminal B breast
cancer subtypes.
A similar comparison using published gene expression data
from TCGA showed that whereas there were other cross-cancer
similarities, the molecular association between breast and blad-
der cancers was relatively strong (SI Appendix, Fig. S4C) (27, 30–
34). Finally, strikingly, applying PAM50 to our meta-dataset of
bladder tumors revealed positive correlations between basal-like
bladder tumors and the basal centroid and luminal bladder
tumors and the luminal A centroid subtype (SI Appendix, Figs. S4
D and E).
To better visualize this association, we hierarchically clustered
the bladder tumors using a comprehensive list of 1,906 genes
(1,426 of which were present in the meta-dataset) that were
previously shown to define the intrinsic subtypes of breast cancer
(29). The breast-specific gene list clustered the bladder tumors
along the lines of basal-like and luminal bladder subtypes (P =
2.2e-16, χ2 test) (SI Appendix, Fig. S4F). Furthermore, gene
signatures representative of basal-like and luminal breast cancers
as well as well-defined breast cancer-related oncogenic pathway
signatures faithfully clustered basal-like and luminal bladder
tumors in both datasets (Fig. 4B and SI Appendix, Fig. S5A).
Basal-like bladder tumors displayed enhanced MYC and E2F3
pathway signatures, whereas luminal tumors appeared enriched
in the set of genes characteristic of the HER2 amplicon. Taken
together, these data strongly demonstrate that the gene expres-
sion patterns that distinguish basal-like and luminal bladder
cancers reflect the RNA expression patterns that define the in-
trinsic subtypes of breast cancer.
A Subset of Basal-Like Bladder Tumors Are Claudin-Low. The recently
described claudin-low molecular subtype of breast cancer is
characterized by low expression of the claudin tight junction
proteins (claudins 3, 4, and 7) and up-regulation of epithelial to
mesenchymal transition (EMT) markers as well as stem cell-like
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Fig. 3. Luminal and basal-like bladder cancer have differential survival and
are associated with distinct genomic alterations. (A and B) Kaplan–Meier
plots for muscle-invasive tumors from the MSKCC dataset (≥pT2) were
generated for disease-specific survival (A) and overall survival (B). Basal-like
tumors (n = 22) had a significantly decreased disease-free and overall sur-
vival compared with luminal tumors (n = 16) (P = 0.0194 and 0.0081, re-
spectively). (C) Superficial tumors not included in the generation of BASE47
were subjected to BASE47 subtype prediction. (D) Sequencing and copy
number analysis was performed on common mutations in bladder cancer.
FGFR3 and TSC1 alterations were significantly enriched in luminal bladder
cancer, whereas alterations of the RB1 pathway were enriched in basal-like
bladder cancer. TP53 alterations were distributed evenly in both subtypes.
(E) Basal-like and luminal tumors from the meta-dataset were annotated for
sex (two of four datasets). The prevalence of basal-like bladder cancer was
significantly greater in female patients (P value = 0.0203, χ2 test).
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features (28). Tumors from the meta-dataset were classified
based on an 807 gene signature, which accurately defines clau-
din-low breast cancer (28). Overall, 16% of the meta-dataset
tumors (Fig. 5) and 26% of the MSKCC tumors (SI Appendix, Fig.
S5B) were identified as claudin-low. When clustered based on
genes that define key molecular pathways in claudin-low breast
tumors (breast cancer subtype markers, EMT markers, and TIC
markers) (Fig. 5 and SI Appendix, Fig. S5B) the claudin-low
bladder tumors displayed expression patterns indicative of claudin-
low breast tumors. In addition, whereas all of the claudin-low
tumors were of the basal subtype, they did not appear to have
different disease-specific or overall survival from basal-like bladder
tumors (SI Appendix, Fig. S5 C andD), in keeping with the claudin-
low subtype in breast cancer (28). Thus, a subset of basal-like
bladder tumors have claudin-low features.
Discussion
Using independent discovery in distinct datasets, we have de-
fined two molecular subtypes of high-grade UC with molecular
features reflecting different stages of urothelial differentiation.
Luminal bladder cancers express markers of terminal urothelial
differentiation, such as those seen in umbrella cells (UPK1B,
UPK2, UPK3A, and KRT20), whereas basal-like tumors express
high levels of genes that typically mark urothelial basal cells
(KRT14, KRT5, and KRT6B). The basal cell compartment is
a common feature of most organs with stratified or pseudos-
tratified epithelium. It is characterized by its proximity to the
basement membrane and is thought to harbor multipotent tissue
stem cells important for normal tissue homeostasis and or-
derly regeneration after injury. Because basal cells are a long-
lived population, they are potentially more likely to incur
multiple genomic alterations, including changes in their chro-
matin landscape. In this regard, it is interesting to note that there
appears to be a relatively high prevalence of mutations in his-
tone- and chromatin-modifying genes in UC (3).
The luminal and basal-like subtypes of bladder cancer reflect
many of the hallmarks of the intrinsic breast cancer subtypes. For
example, a number of basal-like and luminal breast cancer-
specific gene signatures were enriched in the corresponding
bladder subtype, including bonafide luminal breast cancer path-
ways, such as GATA3 and estrogen receptor signaling in the
luminal bladder subtype. Moreover, the gene expression patterns
that define luminal and basal-like bladder cancers closely cor-
responded with the gene expression patterns that define luminal
(A and B) and basal-like breast cancers. These similarities may
reflect the presence of urothelial basal cells and their corollary,
the basal/myoepithelial cells of the breast. In both tissues, these
basal cells represent a multipotent “stem/progenitor cell” pop-
ulation (35, 36) and their similar functional roles may explain
their similar molecular profiles.
We identified some differences between the breast and blad-
der cancer intrinsic subtypes as well. For example, whereas we
identified a claudin-low subtype of bladder cancer, in contrast to
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Fig. 4. Basal-like and luminal bladder cancers are correlated with the in-
trinsic molecular subtypes of breast cancer. (A) Median gene expression of
genes present in the breast cancer-specific intrinsic gene list were de-
termined for each bladder and breast subtype, and 1-Pearson correlation
was calculated comparing bladder subtypes (bladder tumors) with breast
subtypes (breast tumors) in both the TCGA and UNC337 breast datasets. (B)
The meta-dataset tumors were run against previously published breast
cancer-related gene sets. The resulting pathway scores were clustered by
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Fig. 5. A subset of basal-like bladder tumors are claudin-low. The meta-
dataset was clustered hierarchically using representative genes known to
define claudin-low breast tumors. Claudin-low subtype designation was
assigned using a previously defined 807-gene signature.











intrinsic subtypes, all of the claudin-low bladder tumors are a
subpopulation of the basal-like subtype. Furthermore, despite a
subset of luminal bladder tumors with elevated expression of
the HER2 amplicon, we did not find any significant correlation
with the Her2-enriched breast subtype using our correlation
matrix (Fig. 4A).
Our study has created a gene signature, BASE47, which ac-
curately discriminates intrinsic bladder subtypes. Interestingly,
even in superficial bladder tumors, there appears to be a signifi-
cant number of basal-like tumors. Although the characteristics of
our meta-dataset did not allow us to determine whether the
subtypes were prognostic or predicted the progression to muscle-
invasive disease in superficial bladder tumors, these are impor-
tant questions with significant clinical implications, such as early
cystectomy for patients with high-grade T1 disease. The ability to
accurately classify basal-like and luminal bladder subtypes with
only 47 genes should allow the adoption of BASE47 to formalin-
fixed, paraffin embedded tissues, allowing its widespread use.
Female patients with UC have inferior outcomes compared
with males with UC, even when controlling for other known
prognostic variables, such as stage and grade (24). Interestingly,
we found that females have an increased incidence of basal-like
bladder cancer, which is associated with worse outcomes. To the
extent to which this increased prevalence of basal-like bladder
tumors in women contributes to their poorer outcomes remains
unclear. Moreover, whether this association suggests that the
pathogenesis of bladder cancer in females (i.e., chronic inflam-
mation) is different is of interest.
In summary, the basal-like and luminal intrinsic subtypes of
bladder cancer reflect many aspects of urothelial physiological
development, as well as breast cancer biology (Fig. 6 A and B).
These findings underscore the idea of common themes un-
derlying the development and maintenance of solid tumors that
extend beyond overlapping mutational spectra. An appreciation
of subtype heterogeneity has substantially furthered our un-
derstanding of breast cancer biology. Our results suggest that the
intrinsic subtypes of high-grade bladder cancer strikingly reflect
many aspects of breast cancer. It will be particularly interesting
to see whether the bladder subtypes, like the breast subtypes, are
useful in stratification for therapy.
Materials and Methods
Training Dataset Analysis. A meta-dataset was generated by combining the
muscle-invasive (≥T2) UC samples from four publicly available datasets
(GSE13507, GSE31684, GSE32894, and GSE5287) with clinical annotation
provided by the Michor laboratory at Dana-Farber Cancer Institute. The data
were normalized, median-centered by gene, and merged into a single
dataset comprising 262 tumors. The mean absolute deviation (MAD) was
computed across samples by gene. Genes with a MAD score of >0.10 were
selected for clustering analysis (7,303 genes). Consensus hierarchical clus-
tering was performed as described previously (37), with 90% resampling and
1,000 iterations. Two-class SAM (FDR, 0) was performed to generate sub-
type-specific gene lists (38). The significant genes and corresponding fold
changes as determined by SAM were analyzed by IPA (Ingenuity Systems) for
predicted pathway activation. GSEA was performed comparing basal and
luminal tumors against MSigDB.c2.all.v4.0 (39, 40).
Validation Dataset. Gene expression data were derived from 49 high-grade
tumors from MSKCC using human HT-12 expression BeadChip arrays (Illu-
mina) as described previously (8). The MSKCC dataset was normalized and
median-centered, and the MAD was computed across samples by gene.
Genes with a MAD score of >0.10 were selected for clustering analysis (3,357
genes). Consensus clustering was performed identically to the meta-dataset
(37). The resulting subtype assignments for K2 were used to validate the
training dataset. Centroids were generated for both the meta-dataset and
MSKCC dataset using all common genes, and correlations were calculated by
1-Pearson correlation. Copy number alterations and hotspot mutation
analyses were determined as described previously (8).
Subtype Predictor. PAMwas used to determine the minimal number of genes
that could accurately predict subtype classification on themeta-dataset, using
the consensus clustering calls as a reference (41). The resulting 47-gene
predictor (Δ = 6.3) was used to classify the MSKCC samples (41). Tumors were
then analyzed for enrichment of mutations or copy number alterations (8)
by the χ2 or Fisher exact test as appropriate. Categorical survival analyses
were performed using the log-rank test and visualized with Kaplan–Meier
plots. BASE47 was then applied to superficial tumors, which were excluded
from the meta-dataset. The superficial tumors were normalized and median-
centered as described previously, and BASE47 calls were made using PAM.
Correlation with Breast Cancer. TCGA (27) and UNC337 (GSE18229) breast
mRNA datasets were log-transformed and median centered. Breast and
bladder subtypes were correlated using Pearson correlation (visualized as
1-Pearson) by the median gene expression of the breast cancer intrinsic gene
list (29). PAM50 calls were made on the individual datasets that composed
the meta-dataset and the MSKCC dataset as described previously (29). Breast
cancer signature enrichment was performed as described previously (42).
Samples were hierarchically clustered and visualized on a heatmap. Claudin-
low subtype calls were made as described previously (28).
Note Added in Proof. During the course of our studies, we became aware
of the work by Choi et al. (43) whose results independently demon-
strate the existence of basal and luminal subtypes of high grade bladder
cancers with molecular features that resemble their corresponding breast
cancer subtypes.
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Fig. 6. Proposed model of urothelial tumorigenesis and relationships with
intrinsic subtypes of breast cancer. (A) Low-grade (LG) and high-grade (HG)
UCs are associated with specific genetic alterations. Low-grade papillary
tumors often incur FGFR3, RAS, and receptor tyrosine kinase alterations,
whereas high-grade tumors are characterized by loss of tumor-suppressor
genes, such as PTEN, TP53, and RB1 pathway alterations. Whereas most low-
grade tumors recur as low-grade, a small proportion progress to high-grade
tumors in association with PTEN, TP53, and RB1 pathway alterations. We
propose that low-grade tumors that progress are likely to be high-grade
papillary tumors of the luminal molecular subtype, and that de novo high-
grade tumors are likely to be of the basal-like expression subtype. Whether
luminal, nonpapillary tumors arise from low-grade tumors is unclear. (B)
Diagram showing the proposed relationship between intrinsic subtypes of
breast and bladder cancers.
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